UPDATE 1-U.S. approves GSK, Xenoport drug for new use
LONDON, June 7
LONDON, June 7 (Reuters) - GlaxoSmithKline and XenoPort have received approval from the U.S. Food and Drug Administration to sell Horizant to treat post-herpetic neuralgia, the companies said on Thursday.
The medicine is already approved as a treatment for restless legs syndrome. XenoPort will receive a milestone payment of $10 million from GSK following first sales of the drug in its new use.
- Tweet this
- Share this
- Digg this
- Ukraine says pro-Russia rebels shoot down two fighter jets
- U.N.'s Pillay says Israel may be committing war crimes
- South Korea ferry fugitive hid behind cabin wall, bags of cash at hand
- China's Xiaomi hopes Mi 4 smartphone can take on Apple
- Jet Airways chairman says looking to restructure debts, talking to bankers